Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Sad-otc
INDICATIONS [/za_1298.html#1] [/za_1298.html#1] [/za_1298.html#1] CONTRA-INDICATIONS [/za_1298.html#1] [/za_1298.html#1] DOSAGE [/za_1298.html#1] [/za_1298.html#1] SIDE-EFFECTS [/za_1298.html#1] [/za_1298.html#1] PREGNANCY [/za_1298.html#1] OVERDOSE [/za_1298.html#1] IDENTIFICATION [/za_1298.html#1] [/za_1298.html#1] PATIENT INFORMATION INFACET SYRUP SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): INFACET SYRUP COMPOSITION: Each 5 mL contains: PROMETHAZINE Hydrochloride 7,0 mg CODEINE Phosphate 5,0 mg PARACETAMOL 120,0 mg PHENYLPROPANOLAMINE Hydrochloride 2,5 mg Alcohol 96 % 20,0 % v/v PRESERVATIVES: Propyl hydroxybenzoate 0,01 % m/v Methyl hydroxybenzoate 0,10 % m/v PHARMACOLOGICAL CLASSIFICATION: A 2.8 Special Analgesic combinations. PHARMACOLOGICAL ACTION: Analgesic, antipyretic, decongestant syrup, for paediatric use. INDICATIONS: For the alleviation of mild to moderate pain and fever in infants and children and for nasal congestion associated with colds, influenza and sinusitis. CONTRA-INDICATIONS: Infacet Syrup should not be used by epileptics or in conjunction with M.A.O. inhibitors. It must be used with caution in patients with hepatic or kidney disease, cardiac disorders, hypertension, hyperthyroidism or diabetes mellitus. Contra- indicated in cases of hypersensitivity to any of the ingredients. WARNINGS: 1. INFACET SYRUP SHOULD NOT BE USED CONTINUOUSLY FOR MORE THAN 10 DAYS WITHOUT CONSULTING YOUR DOCTOR. 2. THIS MEDICINE MAY LEAD TO DROWSINESS AND IMPAIRED CONCENTRATION, WHICH MAY BE AGGRAVATED BY SIMULTANEOUS INTAKE OF ALCOHOL OR OTHER Read the complete document